Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 503


Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.

Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C.

Clin Gastroenterol Hepatol. 2020 Feb 13. pii: S1542-3565(20)30174-9. doi: 10.1016/j.cgh.2020.02.010. [Epub ahead of print]


Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.

Sifers T, Hirten R, Mehandru S, Ko HM, Colombel JF, Cunningham-Rundles C.

Clin Immunol. 2020 Feb 11;212:108362. doi: 10.1016/j.clim.2020.108362. [Epub ahead of print]


Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J.

Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30167-0. doi: 10.1053/j.gastro.2020.01.047. [Epub ahead of print]


JAK inhibitors safety in ulcerative colitis: practical implications.

Agrawal M, Kim ES, Colombel JF.

J Crohns Colitis. 2020 Feb 1. pii: jjaa017. doi: 10.1093/ecco-jcc/jjaa017. [Epub ahead of print]


A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.

Hirten RP, Lakatos PL, Halfvarson J, Colombel JF.

Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31499-5. doi: 10.1016/j.cgh.2019.12.019. [Epub ahead of print] Review.


Crohn's disease patients' and gastroenterologists' perspectives towards de-escalating inflammatory bowel disease therapy.

Siegel CA, Thompson KD, Walls D, Gollins J, Buisson A, Olympie A, Beaugerie L, Colombel JF, Louis E; BIOCYCLE group.

Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31498-3. doi: 10.1016/j.cgh.2019.11.062. [Epub ahead of print] No abstract available.


Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).

Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, Dupas JL, Fumery M, Paupard T, Catteau S, Deplanque D, Colombel JF, Desreumaux P.

J Clin Med. 2019 Dec 24;9(1). pii: E41. doi: 10.3390/jcm9010041.


A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*.

Aliment Pharmacol Ther. 2020 Mar;51(5):553-564. doi: 10.1111/apt.15609. Epub 2019 Dec 22.


New Blood Marker of Endoscopic Disease Activity-A Step Forward in Treating Crohn's Disease to Target?

Agrawal M, Ungaro RC, Colombel JF.

Gastroenterology. 2020 Feb;158(3):463-465. doi: 10.1053/j.gastro.2019.12.015. Epub 2019 Dec 19. No abstract available.


Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.

Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Colombel JF, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G.

Am J Gastroenterol. 2019 Dec 16. doi: 10.14309/ajg.0000000000000493. [Epub ahead of print]


De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.

Chapman TP, Gomes CF, Louis E, Colombel JF, Satsangi J.

Lancet Gastroenterol Hepatol. 2020 Jan;5(1):63-79. doi: 10.1016/S2468-1253(19)30186-4. Review.


Review article: bacteriophages in gastroenterology-from biology to clinical applications.

Sabino J, Hirten RP, Colombel JF.

Aliment Pharmacol Ther. 2020 Jan;51(1):53-63. doi: 10.1111/apt.15557. Epub 2019 Nov 7. Review.


Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.

Aliment Pharmacol Ther. 2020 Jan;51(2):271-280. doi: 10.1111/apt.15555. Epub 2019 Oct 29.


Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.

Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ.

Inflamm Bowel Dis. 2020 Jan 6;26(2):304-313. doi: 10.1093/ibd/izz241.


Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence.

Hirten RP, Ungaro RC, Castaneda D, Lopatin S, Sands BE, Colombel JF, Cohen BL.

Inflamm Bowel Dis. 2019 Oct 19. pii: izz224. doi: 10.1093/ibd/izz224. [Epub ahead of print]


Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases.

Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS.

Gastroenterology. 2020 Jan;158(1):95-110. doi: 10.1053/j.gastro.2019.08.060. Epub 2019 Oct 15. Review.


Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients.

Kayal M, Plietz M, Rizvi A, Radcliffe M, Riggs A, Yzet C, Tixier E, Trivedi P, Ungaro RC, Khaitov S, Sylla P, Greenstein A, Frederic Colombel J, Dubinsky MC.

Inflamm Bowel Dis. 2019 Oct 6. pii: izz227. doi: 10.1093/ibd/izz227. [Epub ahead of print]


Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis.

Kayal M, Plietz M, Radcliffe M, Rizvi A, Yzet C, Tixier E, Hirten RP, Cohen B, Sylla P, Khaitov S, Greenstein A, Colombel JF, Dubinsky MC, Ungaro RC.

Aliment Pharmacol Ther. 2019 Dec;50(11-12):1189-1194. doi: 10.1111/apt.15505. Epub 2019 Oct 3.


Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group.

N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.


Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study.

Kayal M, Saha A, Poojary P, Paramsothy S, Hirten R, Cohen L, Gallinger Z, Mehandru S, Cho J, Greenstein A, Nadkarni G, Dubinsky MC, Colombel JF, Cohen B, Ungaro R.

Int J Colorectal Dis. 2019 Oct;34(10):1771-1779. doi: 10.1007/s00384-019-03375-2. Epub 2019 Sep 11.


Supplemental Content

Loading ...
Support Center